Clinical Trials Logo

Filter by:
NCT ID: NCT03154619 Active, not recruiting - Venous Leg Ulcer Clinical Trials

Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers

Start date: November 2016
Phase: Phase 2
Study type: Interventional

The safety and efficacy of beta glucan products, and specifically TR 987, in the treatment of chronic venous insufficiency ulcers has been established. This study is designed to determine the most efficient method of treatment.

NCT ID: NCT03154346 Active, not recruiting - All Clinical Trials

Project Baseline Health Study

Start date: March 29, 2017
Phase:
Study type: Observational [Patient Registry]

This study is the first initiative of Project Baseline, a broader effort designed to develop a well-defined reference, or "baseline," of good health as well as a rich data platform that may be used to better understand the transition from health to disease and identify additional risk factors for disease. Project Baseline endeavors to test and develop new tools and technologies to collect, organize, and activate health information.

NCT ID: NCT03154294 Active, not recruiting - Clinical trials for Advanced Solid Tumor

Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors

Start date: July 6, 2017
Phase: Phase 1
Study type: Interventional

This is an open-label, cohort study to determine the feasibility and tolerability of the combination of TAK-228 and TAK-117 given on days 2-4, 9-11, 16-18, and 23-25 with paclitaxel on days 1, 8, and 15 for one 28-day cycle in patients with advanced solid tumors.

NCT ID: NCT03154281 Active, not recruiting - Breast Cancer Clinical Trials

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Start date: July 17, 2017
Phase: Phase 1
Study type: Interventional

Open-label, cohort study to determine the feasibility and tolerability of the combination of daily niraparib and daily or thrice weekly everolimus for one 28-day cycle in patients with advanced ovarian and breast cancer.

NCT ID: NCT03154190 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

Start date: August 8, 2017
Phase: N/A
Study type: Interventional

This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer. Health care coach support may help cancer patients to make decisions about their care that matches what is important to them with symptom management.

NCT ID: NCT03153488 Active, not recruiting - Clinical trials for Attention Deficit Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder (ADHD) Prediction of Treatment Response

Start date: July 1, 2018
Phase: N/A
Study type: Interventional

This is a 6-month trial in adults to find out if certain neuromarkers can predict individual treatment response to stimulant medications for Attention Deficit Hyperactivity Disorder (ADHD). Males and females, ages 18-45, will complete an MRI scan at MIT prior to beginning medication for ADHD as determined by a treating clinician outside the context of this study.

NCT ID: NCT03153475 Active, not recruiting - Clinical trials for Revision Total Knee Arthroplasty

ATTUNE Revision System in the Revision Total Knee Arthroplasty Population

Start date: May 30, 2017
Phase: N/A
Study type: Interventional

Five-year, Prospective, multi-center, non-randomized, non-controlled study of the ATTUNE® Revision total knee prostheses, utilizing the fixed bearing (FB) and rotating platform (RP) tibial component with the posterior stabilizing (PS) femoral component in revision total knee arthroplasty.

NCT ID: NCT03153319 Active, not recruiting - Clinical trials for Mucopolysaccharidosis II

Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI

Start date: June 5, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by open-label phase, to evaluate the effects of adalimumab compared to placebo on the change from baseline in joint and skeletal disease in children and adults with mucopolysaccharidosis (MPS) I, II or VI.

NCT ID: NCT03151564 Active, not recruiting - Liver Metastases Clinical Trials

Lesion Detection Assessment in the Liver: Standard vs Low Radiation Dose Using Varied Post-Processing Techniques

Start date: May 9, 2017
Phase: N/A
Study type: Interventional

To compare 2 different image creation/processing techniques during a standard CT scan in order to "see" problems in the liver and learn which method provides better image quality. The techniques use new artificial intelligence software to decrease image noise, which helps the radiologist to evaluate.

NCT ID: NCT03151330 Active, not recruiting - Preterm Birth Clinical Trials

Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls: AVERT PRETERM TRIAL

Start date: June 15, 2018
Phase: N/A
Study type: Interventional

Background: Preterm birth (PTB) remains the leading cause of neonatal mortality and long term disability throughout the world. Recently treatments early in pregnancy such as progesterone, cervical support and maternal support have been demonstrated to delay delivery amongst at risk women. Nonetheless, the majority of women who are at risk are not identified using current screening modalities. Hypothesis: A cohort of pregnancies who are screened using the PreTRM® test around 20 weeks gestation in which a bundle of interventions is given for elevated PreTRM® risk will show either decreased neonatal morbidity/and mortality (measured as a composite score, "NMI"), or decreased length of neonatal stay in the hospital (NNOLOS). Secondarily, they will show an increase in gestational age at birth (GAB) and a reduction in length of neonatal NICU stay (NICULOS), compared to an unscreened historical control group. Study Design Type: Prospective cohort study of screened women compared to a historical control of 10000 women.